Clinical Trials Logo

Status Epilepticus clinical trials

View clinical trials related to Status Epilepticus.

Filter by:

NCT ID: NCT05674552 Recruiting - Status Epilepticus Clinical Trials

Exogenous Ketone Esters for Refractory Status Epileptics

EKERSE
Start date: January 10, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to investigate the efficacy of add-on exogenous ketone esters for the treatment of children with refractory generalized convulsive status epilepticus

NCT ID: NCT05647525 Completed - Status Epilepticus Clinical Trials

The Etiology of New-onset Status Epilepticus

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.

NCT ID: NCT05591508 Recruiting - Status Epilepticus Clinical Trials

Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Ketogenic diet being started early in those with status epilepticus and frequent or abundant discharges in EEG in comparison to just standard therapy is being evaluated here for efficacy and adverse effects.

NCT ID: NCT05491590 Recruiting - Intensive Care Unit Clinical Trials

Patient-reported Outcome After Status Epilepticus

POSEIDON
Start date: November 9, 2022
Phase:
Study type: Observational

Status epilepticus (SE) is a common life-threatening neurological emergency in which prolonged or multiple closely spaced seizures can result in long-term impairments. SE remains associated with considerable mortality and morbidity, with little progress over the last three decades. The proportion of patients who die in the hospital is about 20% overall and 40% in patients with refractory SE. Morbidity is more difficult to evaluate, as adverse effects of SE are often difficult to differentiate from those attributed to the cause of SE. Our experience suggests that nearly 50% of patients may experience long-term functional impairments. The precise description of the consequences of these functional impairments and their impact on quality of life after SE requiring intensive care management has been little studied. Indeed, if cognitive, physical and mental impairments are now identified in the populations of patients who required intensive care under the term post-resuscitation syndrome (PICS), neuronal lesions consecutive to the SE itself or to its cause could be responsible for these different functional alterations. Thus, the following have been described: (i) cognitive disorders in the areas of attention, executive functions and verbal fluency, visual and working memory disorders, but also spatio-temporal disorders; (ii) physical disorders such as the so-called post-resuscitation polyneuromyopathy; and (iii) mental disorders such as anxiety disorders, depressive states or those related to post-traumatic stress. Assessment and characterization of patient-reported outcomes is essential to complement the holistic assessment of clinically relevant outcomes from the patient's perspective. Here, we propose the development of a cross-sectional collection of PROs of the different constituents of PICs and HR-QOLs, and associated with functional patient outcomes, in those who required ICU management for status epilepticus.

NCT ID: NCT05418634 Recruiting - Status Epilepticus Clinical Trials

Point-of-care EEG in the Pediatric Emergency Department

Start date: August 24, 2022
Phase:
Study type: Observational

The researchers investigate the use of a simplified electroencephalogram (point-of-care EEG) in the pediatric emergency department for children with impaired consciousness or an ongoing epileptic seizure ("status epilepticus"). In addition, the researchers will compare the simplified EEG with the conventional EEG in the epilepsy outpatient clinic.

NCT ID: NCT05346666 Recruiting - Epilepsy Clinical Trials

Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

Start date: June 25, 2022
Phase: Phase 3
Study type: Interventional

Recently, the pathogenesis of epilepsy is immuno-modulatory and neuro-inflammatory which is commonly activated in epileptogenic brain regions in humans and is clearly involved in animal models of epilepsy. Inflammatory mediators in the blood and molecular imaging of neuro-inflammation could provide diagnostic, prognostic, and predictive biomarkers for epilepsy, which will be instrumental for patient stratification in future clinical studies. Dysfunction of the blood-brain barrier (BBB) may be responsible for abnormal neuronal firing. Disruption of the BBB causes the leakage of serum protein and leucocyte invasion into the brain. These exogenous inflammatory mediators have the potential to lower seizure thresholds, which could alter channel sensitivity, neurotransmitter uptake or release, and glia-associated regulation of extracellular environments, such as potassium concentration.

NCT ID: NCT05291455 Recruiting - Epilepsy Clinical Trials

Lacosamide in Neonatal Status Epilepticus

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

Lacosamide in neonatal status epilepticus

NCT ID: NCT05267405 Recruiting - Epilepsy Clinical Trials

Mainz Epilepsy Registry

MAINZ-EPIREG
Start date: February 1, 2018
Phase:
Study type: Observational [Patient Registry]

Prospective longitudinal observational registry study of all patients with epilepsy treated in the Mainz Comprehensive Epilepsy and Sleep Medicine Center with the focus on the course of the disease and quality of life.

NCT ID: NCT05263674 Recruiting - Clinical trials for Non-Convulsive Status Epilepticus

Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)

FAST
Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

This open-label, randomized multicenter trial aims at clarifying the standard of care of patients with non-convulsive status epilepticus not responding to treatment with benzodiazepines and at least one high-dose intra venous anti-seizure medication.

NCT ID: NCT05259891 Completed - Epilepsy Clinical Trials

eegCap Application in Paediatrics wiTh redUced GCS in REsus

CAPTURE
Start date: July 5, 2021
Phase:
Study type: Observational

Children frequently present with altered or reduced consciousness levels to emergency departments. By using EEG monitoring, subclinical seizure activity may be detected, leading to earlier pharmacological intervention and improved outcomes. Post-ictal phases that may be interpreted as seizure activity may become less over-treated. A feasibility study will ascertain if EEG monitoring can be applied successfully in this cohort, within a specified time period, obtaining minimum artefact (defined as < 25% artefact). EEG recordings will not be used to guide clinical management during this feasibility study.